Lifeboat Foundation

Take a look at Goodyear’s vision for the future of transport.

The role of epigenetics, which determine how your genes are expressed, is being increasingly implicated in aging, as is the potential of therapies that revert epigenetics back to those of a younger person.

What are epigenetic alterations?

The DNA in each of our cells is identical, with only some small variations, so why do our various organs and tissues look so different, and how do cells know what to become?

Continue reading “Epigenetic Alterations and Reprogramming Potential in Aging” »

https://paper.li/e-1437691924

Multiple users are reporting on social media that they are currently unable to delete their Coinbase accounts. This news comes as some cryptocurrency enthusiasts continue to clamor for a boycott of the exchange giant over its recent acquisition of Neutrino.

Amid the clamor for a boycott on Coinbase, some users are saying that the company is preventing them from closing down their accounts. Respondents say they followed the fairly easy account closing procedure only to be met with error messages.

Continue reading “Coinbase Preventing Account Closures as #DeleteCoinbase Movement Spreads” »

Scientists have long tried to duplicate the procedure that led to the first long-term remission 12 years ago. With the so-called London patient, they seem to have succeeded.

As more time passes since the Big Bang, more of the Universe comes into view. But how much?

ENIAC was the world’s first electronic digital computer, and though it was glossed over in the history books, it was programmed by a team of six women. Remembering their contributions could inspire young women looking to break into the male-dominated tech industry.

To stay at the top of the tycoon pile, developers are quickly diversifying, embracing the government’s new pet industry – tech.

Astronauts or astro-nots?

A study published today in the journal Nature Medicine led by researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) describes a new therapeutic approach with potential for patients with pancreatic cancer. These researchers discovered a combination drug therapy that may effectively combat the disease. HCI researchers first observed anti-cancer impacts in a laboratory setting and, subsequently, in its first use in a human patient.

The study has already progressed to a clinical trial that is now open at HCI and will soon be open at other sites in the United States. Details about the clinical trial, called THREAD, are available under National Clinical Trial Number 03825289. The combination therapy uses two drugs already approved for use by the Food and Drug Administration for other diseases, including cancer. The new drug combination is administered through pills taken orally.

Pancreatic tumors are characterized by mutations in a gene called KRAS. When KRAS is mutated in this way, it sends constant signals that promote abnormal cell division and growth in cancer cells. As a result, tumors grow out of control. At the same time, like all cells, pancreatic cancer cells must recycle their components to provide building blocks for new growth in an essential cell function known as autophagy. Previous studies to combat pancreatic cancer that were focused either on the role of KRAS or on impacting autophagy were not effective.